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Investigations into the genetics of child psychiatric disorders have finally begun to shed light on molecular
and cellular mechanisms of psychopathology. The first strains of success in this notoriously difficult area
of inquiry are the result of an increasingly sophisticated appreciation of the allelic architecture of common
neuropsychiatric and neurodevelopmental disorders, the consolidation of large patient cohorts now begin-
ning to reach sufficient size to power reliable studies, the emergence of genomic tools enabling comprehen-
sive investigations of rare aswell as common genetic variation, and advances in developmental neuroscience
that are fueling the rapid translation of genetic findings.In many ways it is truly the best of times.
However, as excitement justifiably mounts that the field is
finally gaining a scientific foothold, a survey of recent findings
points to both continuing and emerging challenges. The early
application of mature genomic technologies that are providing
unequivocal, if not comprehensive, insights into the contribution
of common variants to common medical conditions (Altshuler
et al., 2008) have so far not revealed definitive findings in child
psychiatry, reinforcing the conclusion that the genetics of these
disorders are particularly difficult to decipher; current gene
discovery efforts in a number of childhood and adult disorders
are challenging the biological relevance of the psychiatric diag-
nostic nosology, and the ability to leverage advances in neuro-
science promises to remain both a blessing and a curse: on
the one hand, the contribution of neurobiological data to clari-
fying genetic findings and driving translational efforts is indispen-
sible. At the same time, the lure of substituting biological plausi-
bility for accepted standards of evidence in genetic or genomic
analyses, coupled with the rapid accumulation of massive
amounts of sequence and structural variation in affected individ-
uals, risks a proliferation of extremely intriguing, but ultimately
misguided, neurobiological narratives.
This review will aim to address both sides of the coin: the
tremendous promise as well as the challenges facing child
psychiatric genetics. The first three sections will address the
changing conceptions of the allelic architecture of common
disorders, the attendant emerging focus on rare variation in child
psychiatry, and the causes and consequences of an increasing
reliance on case control association methodology. The review
will then turn to consider gene discovery efforts in two paradig-
matic childhood disorders: autism and Tourette syndrome,
focusing on recent finding, their roles in illuminating pathophys-
iological mechanisms, and the likely future of human genetic
endeavors in these areas.
The Allelic Architecture of Child Psychiatric Disorders
Relatively early in the history of genetics of common child
psychiatric disorders it became clear that writ large these did254 Neuron 68, October 21, 2010 ª2010 Elsevier Inc.not obey simple Mendelian expectations. This consensus led
to the ascendance of the ‘‘common variant common disease
hypothesis’’ (CVCD) as the predominant paradigm in the field
(Chakravarti, 1999; Reich and Lander, 2001; Risch and Merikan-
gas, 1996): The expectation was that any given common allele
(defined here as 5% or greater population frequency) would
carry moderate effects and was likely to be neither necessary
nor sufficient to lead to the clinical phenotype. Indeed the notion
was that a combination of risk alleles would contribute to the
emergence of pathological traits falling at the extremes of a pop-
ulation distribution. Consistent with this view is the notion that
family members will tend to demonstrate subclinical manifesta-
tions of a phenotype of interest due to the presence of some,
but not all, risk alleles and that one of the primary objectives of
human genetic research would be to account for all or most of
these common genetic risks shared by the population. The
combination of the CVCD paradigm along with steadily
increasing estimates of the number of genes anticipated to
play a role in neuropsychiatric disorders led to the related
conclusion that association methodologies, demonstrating that
a particular common allele was overrepresented in the popula-
tion of affected individuals, would be themost powerful and prof-
itable avenue to gene discovery.
A convergence of the common variant paradigmwith the tech-
nical feasibility of genotyping one or a small number of common
alleles led to a plethora of candidate gene association analyses
throughout the 1990s and into the early part of this century.
Indeed for many years, the study of child psychiatric genetics
was essentially synonymous with this approach. Unfortunately,
the reliability of these studies proved to be poor (Hirschhorn
et al., 2002; Lohmueller et al., 2003). To those outside the field,
a steady stream of plausible but routinely contradictory findings
began to cast doubt on the entire enterprise.
However, over the past few years, the emergence of highly
reproducible associations from genome-wide association
(GWAS) studies across a variety of medical fields has clarified
many of the reasons for these difficulties (Altshuler et al., 2008;
Manolio, 2010): first, the effect size of common alleles
Figure 1. Relationship between Allele Frequency and Effect Size
The upper dotted curve shows the hypothesized relationship of allele
frequency (x axis) to effect size (y axis), prior to genome-wide approaches to
association, and the lower curve represents the shift resulting from data
emerging from GWAS studies. The blue box highlights the likely contribution
to ASD of low-frequency alleles carrying risks that are greater than those
conferred by common alleles, but not of the scale identifed in rare Mendelian
disorders. The red arrow at the top of the diagram represents the shift toward
association approaches that is required to identify variants that are neither
necessary nor sufficient for the emergence of a phenotype.
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than previously anticipated; second, the prior probability that
any chosen candidate gene or allele will be associated with the
phenotype of interest is extremely low, even given themost plau-
sible biological hypotheses. This reality that has been under-
scored by the very small number of previously suspected loci
that have been confirmed by unbiased genome wide analyses.
Finally, the methodological confounds to association studies,
particularly attending case control approaches, are more prob-
lematic than initially suspected.
With regard to this last point, several key issues are particularly
relevant: for example, the degree to which subtle differences in
ancestry among cases and controls, known as population strat-
ification, could derail analyses was appreciated but the methods
available initially to control for this confound were rudimentary
and later found to be inadequate. The presumption that grouping
by observable characteristics or self-reported ethnicity would be
sufficient was incorrect. Fortunately, the large amount of varia-
tion now detected by genome-wide genotyping allows for
precise matching of cases and controls. And while there remains
some debate over how thoroughly even these methods can
protect against this confound (McClellan and King, 2010), there
is little question that the failure to address ancestry in a rigorous
fashion contributed to the large number of nonreplicated studies.
Similarly, candidate gene analyses often tended to underesti-
mate the impact of pedestrian confounds such as genotyping
error or batch effects.
These difficulties are of more than historical interest: a
surprising number of studies continue to underestimate these
issues; while the problem of population stratification is acknowl-
edged (Tost et al., 2010), few ‘‘imaging genomic’’ studies, those
aimed at investigating the relationship between genetic variation
and functional or structural neuroimaging phenotypes, use
methods that would be considered state-of-the-art within the
genetics community to control for this, and even contemporary
GWAS studies may still fall prey to cryptic technical artifacts (Se-
bastiani et al., 2010). Importantly, as will be discussed below,
a key consideration for the future is that as many fields, including
child psychiatry, increasingly employ case-control methods to
study the contribution of rare alleles, similar liabilities must be
anticipated in the analyses of both copy number variation and
next generation sequencing data.
The Ascendance of Rare Variant Approaches in Child
Psychiatry
Despite the clear numerical predominance of common variant
studies in child psychiatry, rare variant approaches have
a long history in the field and recent interest in these strategies
has risen dramatically. This has been a consequence of an
increasing recognition of the relevance of early rare variant find-
ings, the development of CNV and next-generation sequencing
platforms, and a consensus that GWAS studies have identified
only a small proportion of the anticipate genetic risk for
common disorders and that the ‘‘missing inheritance’’ may be
accounted for in part by rare alleles (Goldstein, 2009; Manolio
et al., 2009).
Before addressing specific findings in autism and Tourette
syndrome, it is worthwhile to differentiate between two comple-mentary but distinct approaches to conceptualizing rare variant
analyses: i.e., ‘‘outlier’’ strategies versus methods based on
a rare variant common disease (RVCD) hypothesis.
The rationale for outlier studies is that some, potentially very
small, proportion of the allelic architecture for a complex
disorder will be accounted for by low frequency variants of large
effect, including Mendelian forms of a condition. This view is
based on the notion that, particularly for early onset disorders,
natural selection will tend to ensure a predictable, inverse rela-
tionship between allele frequency and effect size (Figure 1).
This approach tends to disaggregate common phenotypes:
disorders are not attacked writ large but with a focus on finding
often extremely rare examples that promise to shed light on bio-
logical mechanisms relevant to more common examples of the
phenotype. This emphasis poses an important contrast to at
least the initial rationale for common variant studies by priori-
tizing traction with regard to pathophysiology over the effort to
clarify population genetic risks.
This outlier approach is entirely consistent with but differs
somewhat from studies based on a rare variant common disease
(RVCD) hypothesis. Specifically, in contrast to the minimalist
expectations regarding the role of rare variation in common
disorders reflected in outlier studies and the tendency for these
to focus on the extremes of a phenotypic spectrum, the RVCD
paradigm posits specifically that rare variants will carry a signifi-
cant portion, if not the majority, of population risk for a common
disorder. This RVCD hypothesis has been recently pursuedNeuron 68, October 21, 2010 ª2010 Elsevier Inc. 255
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sequencing studies of, for example, blood pressure regulation
(Ji et al., 2008), cholesterol, and lipid metabolism (Cohen et al.,
2004; Johansen et al., 2010) and autism (Bakkaloglu et al.,
2008). With the advent of next generation sequencing, such
studies promise to proliferate dramatically.
Already, these types of studies have engendered an important
reevaluation of themanner in which rare variation may contribute
to common disease: historically, rare variation has been synon-
ymous with alleles of very large effect (Figure 1). Indeed, given
the methods previously employed to detect rare disease alleles,
most discoveries involved Mendelian inheritance, with the atten-
dant demonstration that within the pedigrees being studied, the
offending rare allele was necessary and largely sufficient to lead
to the phenotype of interest. However, just as has been the case
with common variants, recent studies suggest that rare alleles
may be carrying smaller than anticipated effects without
evidence of being necessary or sufficient to confer a phenotype
(Bucan et al., 2009). A key corollary relates to the relationship
between the effect size of a given allele, its frequency in the pop-
ulation, and the availablemethods to detect and confirm the rela-
tionship to disease (Figure 1). As common variant findings
refocus expectations on alleles with extremely small risks, the
spectrum of genetic effects anticipated for rare alleles neces-
sarily expands, resulting in a shift in the approaches that would
be required to identify this contribution.
The Utility and Pitfalls of Genetic Association
As a consequence, association studies in general, and case-
control designs in particular, promise to play a major role in ad-
dressing the genetic risks in child psychiatry despite the
emerging emphasis on rare variants. While this observation
may seem self evident, the tendency to interpret rare variant find-
ings based on vestigial expectations derived from Mendelian
disorders can be quite powerful. There is a strong innate skepti-
cism that tends to accompany the observation of rare mutations
that are neither necessary nor sufficient to confer a phenotype,
as for instance when a putative disease-related rare mutation
is not always shared by affected siblings (Bucan et al., 2009; Ku-
mar et al., 2008; Weiss et al., 2008).
An increasing reliance on case-control analyses will also result
as a consequence of the emerging ability to detect de novo vari-
ation on a genome wide scale. While such mutations may carry
very large risks, linkageanalysesarenotplausiblegiven thenature
of the variation. Moreover, the prior conventional wisdom that de
novo losses of coding segments providedprima face evidence for
disease causality has been definitively laid to rest (Iafrate et al.,
2004; Sebat et al., 2004). Consequently, carefully controlled
case-control analyses will be required to confirm the relevance
of many de novo variants, particularly in those instances in which
the penetrance of a given mutation is not 100 percent.
Of course, there is little reason to expect that the types of
confounds attending common variant association studies will
be any less pressing for rare sequence and structural variation.
For example, power will certainly remain a critically important
issue: the ability to detect association is a function both of effect
size (larger for rare variants) and allele frequency in the study
population (smaller for rare variants). This tradeoff suggests256 Neuron 68, October 21, 2010 ª2010 Elsevier Inc.that some rare variants carrying modest effects will be impos-
sible to detect given inherent limitations in sample sizes that
can be consolidated.
Moreover, in the case of CNV analyses, typing error may be
considerably more problematic using current array-based
methods compared to SNP genotyping or sequencing due to
limitations in prediction accuracy and confirmation methods; in
addition, there is considerable sample-to-sample variability
and a clear liability toward batch-effects even when using iden-
tical CNV platforms at differing times or at different laboratories.
A recent elegant study identified these and several other less
obvious method-associated technical challenges confronting
CNV analyses (Craddock et al., 2010).
Similarly, population stratification, though initially downplayed
in studies of rare structural variants, clearly has the potential to
confound results (Merikangas et al., 2009). Finally, given the
expectation of a very high degree of allelic heterogeneity and
the possibility that individual mutations will be fleetingly rare,
approaches to association will likely require cumulative counts
of variations at a given gene, i.e., an analysis of mutation burden
or mutation skew (Bakkaloglu et al., 2008; Cohen et al., 2004,
2006; Ji et al., 2008; Johansen et al., 2010). In these instances,
given the large amount of neutral rare variation in the genome,
the differentiation of functional from incidental mutations may
be critical to confirm true association (Ji et al., 2008). And this
can be a challenging enterprise: the human genome tolerates
a tremendous amount of what would have previously been
presumed to be clearly deleterious variation (Iafrate et al.,
2004; Sebat et al., 2004), and recent evidence suggests accurate
interpretation of the impact of particular alleles will be dependent
on specific knowledge of the biology of the gene(s) and protein(s)
in question (Ji et al., 2008).
The Impact of Next-Generation Sequencing
A comprehensive discussion of new genomic technologies is
beyond the scope of this review. However, it is important to
note that next-generation sequencing is already offering unprec-
edented opportunities to investigate genetic variation, gene
expression, and epigenetic phenomenon. With regard to gene
discovery, the ability to comprehensively identify both sequence
and structural variants in large numbers of individuals promises
to revolutionize the understanding of the allelic architecture
and the specific genetic contributors to childhood neuropsychi-
atric disorders.
While the manner in which these technologies will be most
effectively harnessed remains to be seen, several observations
are warranted here: first, while there is little question that next-
generation sequencing will empower large-scale case-control
studies of rare variation, the field is also likely to see a reemer-
gence of pedigree-based genetic studies. Already, sequencing
the human exome has been shown to be a powerful approach
to mapping rare mutations in the setting of tremendous pheno-
typic heterogeneity and within pedigrees that would have previ-
ously been too small to support traditional linkage analyses
(Bilgu¨var et al., 2010); these developments bode well for outlier
approaches to common complex disorders. More generally,
either multiply-affected families or apparently sporadic pedi-
grees may well offer the most expedient means to sort through
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next generation sequencing.
Finally, while the excitement about these new approaches is
well justified, it is also a certainty than even the most exhaustive
catalog of genetic variation will leave many questions unan-
swered and likely serve as only a first important step in
illuminating the complex interplay of experience, environment,
and biology in influencing normal and pathological brain
development.
Autism and Autism Spectrum Disorders
Autism spectrum disorders are a group of syndromes character-
ized by fundamental deficits in social communication and
language development and accompanied by highly restricted
interests, stereotyped repetitive behaviors, or both. The canon-
ical presentation is defined by deficits in all three areas, whereas
disorders along the spectrum include significant social impair-
ment with or without evidence of impairment in other domains.
(Volkmar et al., 2009).
The evidence for a genetic contribution to ASD is very strong,
based on family and twin studies (Bailey et al., 1995; Folstein and
Rutter, 1977), the overlap of ASD with known genetic disorders
(Fombonne et al., 1997), and recent molecular data (addressed
below). There is a strong male predominance (Volkmar et al.,
2004). Despite ambitious efforts aimed at identifying common
and rare alleles, the number of genes or loci that are accepted
as carrying definitive risk remains small and not immune from
debate. In contrast, the list of intriguing and plausible candidates
(see http://www.mindspec.org/auTSb.html) is proliferating
exponentially, a phenomenon that can make deciphering the
current literature quite difficult.
The absence of specific and sensitive biological markers for
ASD, and the consequent reliance on syndromic categorization
and subjective assessment presents predictable challenges, as
it does in all areas of psychiatry (Volkmar et al., 2009). These
issues extend well beyond the scope of the current discussion;
however, a key phenomenological question that bears directly
on the interpretation of the autism genetics literature involves
the overlap of ASDand intellectual disability (ID), which is present
in approximately 70% of individuals meeting full diagnostic
criteria for autism (Chakrabarti and Fombonne, 2001), and
approximately 45%–50% when one considers the entire range
of ASD diagnoses.
It is important to note here that there is little debate that social
impairment and cognitive delay are readily distinguishable in
individuals with mild to moderate ID. While this differentiation
becomes less reliable in cases of severe to profound delay,
debate over this co-occurrence runs deeper than simple diag-
nostic uncertainty and reflects a historical interest in identifying
specific risks for autism as opposed to ‘‘general disruptions of
brain development.’’ This issue is similarly present with regard
to the study of individuals with ASD and seizure, present in
10%–25% of individuals with autism (Volkmar and Pauls,
2003), and is particularly relevant to the study of syndromic
autism i.e., ASD in the context of a known genetic syndrome or
observed in individuals presenting with marked dysmorphology,
structural brain abnormalities, or other evidence of a genetic
syndrome but absent a known cause.In part, these questions reflect an ongoing debate regarding
whether social disability, characterized in the context of known
genetic disorders, is identical to that observed in idiopathic
ASD (Moss and Howlin, 2009), an issue that may sometimes
be difficult to resolve given the challenges inherent in designing
blinded studies of syndromes characterized by distinctive phys-
ical features. However, there is a second line of reasoning, based
on twin and epidemiological data, that contends that the high
rate of ASD in individuals with ID among clinically ascertained
populations is an epiphenomenon resulting from a normal distri-
bution of autism traits in the population which is made manifest
by relatively poor ‘‘compensatory mechanisms’’ in individuals
with ID (Figure 2A). This view proposes that discovery efforts in
cases of overlapping ID and ASD will identify genes for the
former, that a different set of genes underlie social functioning,
and that the optimal strategy for gene discovery with regard to
autism would focus on the population of ASD without intellectual
disability (Skuse, 2007).
While these debates are ongoing, several considerations
deserve mention: first, in addition to the increasing application
of standardized instruments and blinding methods to enhance
the diagnostic reliability of ASD in the context of known
syndromes, the not infrequent detection of syndromic muta-
tions in individuals with idiopathic ASD is evidence that these
variations may lead to behavioral phenomenon that are, for all
practical purposes, indistinguishable from idiopathic ASD
(e.g., the absence of a known genetic syndrome or clear
evidence of a monogenic disorder). Moreover, given that autism
and related conditions are syndromic diagnoses and manifestly
not unitary biological entities, there would seem to be little
question that individuals that are rigorously characterized with
ASD have ASD.
The more difficult questions of whether it is worthwhile to
search for variants contributing to ASD in the context of ID
and to pursue the biology of rare syndromes in an effort to
understand autism remain contested. As noted above, a central
rationale for outlier strategies is that a genetic variation that is
definitively identified as causing or contributing to ASD regard-
less of co-occurring conditions offers potential traction with re-
gard to cellular and molecular mechanisms of pathogenesis, at
least in those cases. The question of whether this biology is
generalizable remains to be demonstrated. However, there is
solid evidence supporting the use of identical strategies in other
common complex and heterogeneous conditions (Ji et al.,
2008; Romeo et al., 2009). Moreover, as discussed in more
depth below, current evidence already points to some conver-
gence in the molecular mechanisms implicated through the
study of syndromic forms of ASD and those suggested by
genes that have the shown the strongest evidence so far for
contribution to idiopathic ASD (Bourgeron, 2009; Toro et al.,
2010). Finally, the observation that identical mutations may
lead not only to ID and ASD, but to schizophrenia and possibly
other neuropsychiatric disorders (addressed below) would
seem to argue for a model based on the pleiotropy of genes
underlying fundamental neuronal processes (Figure 2B),
a phenomena that is highlighted by recent findings from our
group with regard to the genetics of structural brain disorders
(Bilgu¨var et al., 2010).Neuron 68, October 21, 2010 ª2010 Elsevier Inc. 257
Figure 2. Two Models of the Overlap of ASD and ID
(A) This model represents a view well articulated by Skuse
(2007) that the study of syndromic ASD, or ASD in the pres-
ence of ID, is more likely to identify genes related to intellectual
impairment. Co-occuring ASD is a thought to be largely the
consequence of a reduced compensatory capacity in individ-
uals with ID. In this view, ASD characteristics are normally
distributed in the population and are determined by a distinct
set of genes. Given this model, the pursuit of ASD loci should
focus on individuals who do not have ID. In the graph, the units
on the x axis are standard deviations of a hypothetical
measure of social functioning. An alternative model (B)
focuses on the idea that mutations or variations in ‘‘ASD’’
genes alter fundamental cellular and molecular mechanisms
in the CNS (noted here in shorthand as ‘‘synaptic function’’)
as opposed to determining higher-order processes such as
cognition or social function, that these perterbations set the
stage for a developmental course that is reflected in trajecto-
ries across mutiple domains of CNS function, and that these
trajectories will be influenced both by ‘‘inciting’’ genetic events
as well as other genetic, epigenetic, and environmental
processes. This model would suggest that the early vulnera-
bility confered by genetic variation could ultimately be mani-
fested in a wide variety of clinical diagnoses crossing categor-
ical boundaries. In this case, the identification of rare highly
penetrant alleles would point to biology that is relevant to
a wide range of observed clinical outcomes including ID and
ASD. In the graph, the x axis reflects time and the colored
bars represent hypothetical trajectories in multiple areas of
cognitive, linguistic, and behavioral functioning.
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These debates bear substantially on the interpretation of the
results of gene discovery efforts. An observer inclined to
compartmentalize syndromic ASD or ASD coincident with ID
would likely contend that the field awaits definitive identification
of a risk locus. Someone holding the alternative perspective
would likely mark the cloning of the Fragile X Mental Retardation
Protein (FMRP) as the first autism gene, given a longstanding
and well-documented excess of the ASD phenotype observed
in boys carrying canonical mutations and the repeated observa-
tion of FMRP mutations identified in cohorts of individuals with
idiopathic ASD (Brown et al., 1986; Fombonne et al., 1997; Harris
et al., 2008; Hernandez et al., 2009; Levitas et al., 1983).
A number of other well-defined syndromes have either been
found to have a greater than expected frequency of individuals
with ASD or to have core features that overlap with ASD or
both (Hoffman and State, 2010). Among the substantial list, in
addition to fragile X, the data for an appreciably increased prev-
alence of mutation carriers among cases of idiopathic ASD is so
far best established with regard to tuberous sclerosis (Smalley,
1998; Smalley et al., 1992). Similarly, the overlap among defining
features of syndromes such as Angelman or Rett, and ASD258 Neuron 68, October 21, 2010 ª2010 Elsevier Inc.provides a complementary approach to studying
the biology of autism. The contribution of these
and other rare syndromes to the development of
neurobiological models of pathogenesis is dis-
cussed in ensuing sections.
The first rare coding mutation in individuals with
putative idiopathic ASD was identified in the
neuronal adhesionmolecule, Neuroligin 4X (Jamain
et al., 2003). Based on the prior identification ofrecurrent deletions on the X chromosome in affected individuals,
Thomas Bourgeron’s lab sequenced genes within the interval in
36 sibling pairs and 122 trios and found a truncating frame-shift
mutation inNGLN4X arising de novo in an unaffectedmother and
transmitted to two brothers, one with Asperger syndrome and
the second with ‘‘typical’’ autism. Shortly thereafter, mapping
of a multigenerational pedigree affected with both ID and ASD
by an independent group led to the discovery of a segregating
truncating mutation, nearly identical to the initially reported
NLGN4X mutation (Laumonnier et al., 2004).
Over the ensuing half-decade, this finding has been further
supported by convincing evidence for recurrent de novo muta-
tions in individuals with ASD in SHANK3 a postsynaptic scaf-
folding molecule that forms a complex with neuroligins and falls
within the 22q13.3 microdeletion syndrome region (Figure 3;
Durand et al., 2007; Gauthier et al., 2009; Lim et al., 1999;
Moessner et al., 2007). Moreover, recurrent de novo mutations
in other interacting molecules, including NRXN1 (Kim et al.,
2008; Szatmari et al., 2007) and SHANK2 (Berkel et al., 2010;
Pinto et al., 2010b), functional data showing a role for neuroligins
in the establishment of both excitatory and inhibitory synapses
(Chubykin et al., 2005; Graf et al., 2004; Scheiffele et al., 2000),
Figure 3. Rare ASD Variants in Genes
Encoding Synaptic Proteins
The drawing shows a highly selected and simpli-
fied view of the excitatory synapse highlighting
genes strongly implicated via rare variant studies
of idiopathic ASD (blue boxes) and those identified
through the study of syndromic ASD (red boxes).
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and model systems data (Chadman et al., 2008; Tabuchi et al.,
2007) with regard to the closely-related molecule NGNL3, have
placed NLGN4X among the most widely accepted genetic find-
ings in idiopathic ASD.
Over the last several years a rapidly expanding list of rare
mutations have been described in affected individuals, repre-
senting so many genes in fact that an exhaustive assessment
is not feasible here. However, only a small number yet have the
property of being observed in rigorous studies by multiple inde-
pendent investigators. Among these, in addition to NGLN4X,
SHANK3, and NRXN1, the neuronal adhesion molecule CNTN4
has been identified by our lab and others via molecular cytoge-
netic mapping of de novo rearrangements and CNV analyses
(Fernandez et al., 2004, 2008; Glessner et al., 2009; Roohi
et al., 2009); and, quite recently, SHANK2, was identified both
through the identification of de novo disruptive mutations in
one patient with ID and another with ASD (Berkel et al., 2010)
as well as via a large-scale CNV analysis (Pinto et al., 2010a).
A review of the data regarding another neuronal adhesion
protein, encoded by the gene Contactin Associated Protein 2,
provides a useful example of the state of the field at present,
with intriguing findings falling just short of definitive evidence:
the molecule was first identified as having a role in develop-
mental delay through homozygosity mapping of a rare recessive
frame-shift mutation in the Old-Order Amish population (Strauss
et al., 2006). The report involved a syndrome of intractable
epilepsy accompanied by clinically diagnosed autism. Shortly
thereafter, independent reports provided evidence for variations
in CNTNAP2 in idiopathic ASD. The mapping of a rare de novo
chromosomal rearrangement by our lab disrupting this locus in
a simplex ASD pedigree and the subsequent identification of
multiple rare transmitted, missense substitutions at highly
conserved positions in affected multiplex families (Bakkaloglu
et al., 2008), the simultaneous findings by two independent
groups of common variant association (Alarco´n et al., 2008;
Arking et al., 2008), and a subsequent report of interaction of
CNTNAP2 and FOXP2 along with a association of a common
CNTNAP2 allele in language impairment (Vernes et al., 2008)Neuron 68,generated strong interest in this gene
and led to its characterization by some
authors as a confirmed idiopathic ASD
locus.
However, while the initial mapping of
a rare recessive mutation was quite
compelling, the question of whether and
how either common or rare variation in
this gene contributes to nonsyndromic
ASD remains open. For example, themutation burden analysis conducted by our lab was suggestive,
showing an approximately 2-fold increase in very rare missense
variants in cases versus controls. However, as noted in the initial
publication, the results did not reach statistical significance apart
from a single recurrent transmitted allele for which population
stratification could not be ruled out as a confound. Moreover,
the study lacked the ability to reliably differentiate functional
from incidental mutations in cases and controls. The two simul-
taneous common variant association studies identified different
alleles that carried risk for differing phenotypes: one involving the
diagnosis of ASD and the other mapping a language quantitative
trait locus identified in individuals with ASD. Subsequently, only
one of three published GWAS studies in ASD provided any
support for association of CNTNAP2 with the diagnosis of ASD
and this was quite modest (Anney et al., 2010). Finally, the link
to specific language impairment though statistically significant
and based on a strong a priori hypothesis was nonetheless iden-
tified through a candidate gene association study and replication
has yet to be attempted in a genome-wide analysis.
This characterization is notmeant to call into question the rigor
of the aforementioned studies or to detract from interest in
CNTNAP2. The presence of multiple lines of evidence emerging
nearly simultaneously from independent groups conducting
state-of-the-art studies is unusual in the field and many of the
outstanding questions have simply not yet been tested
adequately to allow for independent replication. Nonetheless,
this summary highlights issues that are reflective of the state of
the science with regard to many of the most intriguing findings
in ASD genetics both with regard to common and rare variants:
underscoring the question of the relationship of syndromic find-
ings to common forms of the disorder and highlighting the chal-
lenges posed by sample size, power, phenotypic heterogeneity,
ancestral matching, and distinguishing functional from neutral
alleles.
Copy Number Variation
Prior to the advent of high-density microarrays and the ability to
detect submicroscopic variations in chromosomal structure,
multiple recurrent chromosomal abnormalities were identified
in individuals with ASD. The most common and highly penetrantOctober 21, 2010 ª2010 Elsevier Inc. 259
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(Baker et al., 1994; Hogart et al., 2010). Rare recurrent deletions
at 2q37, 1q21, 22q11, and 22q13, among others, have also been
identified in affected individuals (Bucan et al., 2009, #4635; Laur-
itsen et al., 1999, #5538).
The importance of submicroscopic copy number variation for
ASD was first reported by Michael Wigler’s lab through the iden-
tification of a marked excess of de novo variations in affected
singleton probands (10%) compared to probands frommultiplex
families (3%) or unaffected controls (1%) (Sebat et al., 2007). A
subsequent genome-wide CNV study (Marshall et al., 2008)
confirmed a several fold increase in these events, and suggested
a cumulative frequency of approximately 5–10 percent in the
simplex ASD population. However, another recent large-scale
study, while identifying de novo variations in 5.6% of simplex
ASD probands, did not find a difference compared to probands
from multiplex families (5.5%) (Pinto et al., 2010a). The reasons
for the variability observed in this third study have not yet been
clarified, although even prior to these results, a hypothesis
emerged that the increased frequency identified by Sebat et al.
(2007) might apply particularly to large events, and conse-
quently, that the increasing resolution of array platforms might
tend to obscure some differences between groups.
The initial study by theWigler lab also included a description of
a 16p11.2 de novo deletion and, subsequently, two groups nearly
simultaneously found a significant association of recurrent de
novo CNVs, including both deletions and duplications (Kumar
et al., 2008;Weiss et al., 2008), at this locus in idiopathic ASD, re-
porting on partially overlapping samples. The finding was
confirmed in a subsequent genome wide investigation of struc-
tural variation (Marshall et al., 2008). Among the threeother recent
large-scale CNV studies, the 16p11.2 finding was not replicated
in one due, in part, to the finding of a higher than reported rate
of 16p11.2 CNVs in the control group (Glessner et al., 2009) and
in two others, an independent assessment was precluded by
extensive sample overlapwith the previously reported cases (Bu-
can et al., 2009; Pinto et al., 2010b). Interestingly, a recent study
of 4284 individuals with ID and multiple congenital anomalies
found 16p11.2 CNVs in 0.3% of cases, consistent with that
seen previously among ASD cohorts (Bijlsma et al., 2009), and
providing further evidence for wide ranging phenotypic manifes-
tations emerging from 16p11.2 variations (discussed below).
The 16p11.2 data serve as an important example of the
manner in which current findings are challenging notions
regarding rare variant contributions to ASD. All four deletions
families reported by Kumar et al. (and described again in Weiss
et al.) included two affected children, and in three of these pedi-
grees, only one of the affected siblings carried the de novo CNV.
As noted, based on Mendelian expectations, the observation
that within multiple small pedigrees the large de novo deletion
was not necessary for the phenotype would raises eyebrows.
Indeed, commenting on the lack of 16p11.2 replication in their
CNV analysis, Glessner and colleagues write that their results
‘‘.indicate that CNVs at the 16p11.2.2 locus may not be suffi-
cient to be causal variants in ASD.’’ (Glessner et al., 2009) In
fact, none of the reports of 16p11.2 provided evidence suggest-
ing that the variant is uniformly necessary or sufficient to lead to
ASD. The issue addressed by these studies is whether this CNV260 Neuron 68, October 21, 2010 ª2010 Elsevier Inc.confers risk. The aforementioned studies and our own prelimi-
nary data from a CNV analysis of nearly a 1000 simplex families,
provides mounting evidence that it does.
Recent CNV studies have also provided interesting data
regarding other previously identified and novel loci. Glessner
et al. (2009) replicated findings at 15q11–13 and 22q11.21, as
well as NRXN1 and CNTN4. As noted, they did not identify
a significant difference in cases versus controls for 16q11.2
nor did they observe an association of CNVs at the SHANK3
locus. Their analyses further highlighted multiple novel loci that
were found to cluster via gene ontology analyses in the ubiquitin
pathway and among molecules categorized as being involved in
neuronal development. Pinto et al., in addition to reporting
evidence for SHANK2 almost simultaneously with a report by
Berkel et al. (2010) identified several additional novel loci and
provided strong evidence for X linked inherited deletions of
DDX53-PTCHD1, with 7 reported males among the cases and
none among 4964 controls. Their pathway analyses highlighted
genes involved in cellular proliferation, projection, and motility,
and GTPase/Ras signaling (Pinto et al., 2010b).
Common Variants
Similar to other child psychiatric disorders, the ASD genetics
effort was initially characterized by a focus on idiopathic forms
of the syndrome, an early inability to identify evidence for single
gene inheritance and, subsequently, a widespread preoccupa-
tion with the CVCD hypothesis, investigated via nonparametric
linkage and candidate gene association studies (Veenstra-Van-
derweele et al., 2004).
With regard to nonparametric linkage, the largest study to date
included 1181 multiplex families (Szatmari et al., 2007) and,
alongwith a dozen others using similar approaches, did not iden-
tify highly significant evidence for linkage or result in themapping
of a common variation that accounted for the linkage signals
identified. It should be noted that these studies are theoretically
capable of identifying either common or rare disease alleles.
They evaluated affected sib pairs for regions of the genome
shared among family members more often than would be ex-
pected by chance and consequently have the advantages of
not requiring an a priori specification of a mode of inheritance
and of being robust to allelic heterogeneity.
A likely explanation for the lack of definitive results is the much
greater than anticipated degree of locus heterogeneity observed
in ASD. Particularly in light of the modest sample sizes em-
ployed, a great diversity of genes all contributing to ASD would
tend to obscure evidence for excess sharing at any given locus.
However, as noted previously, with the advent of next generation
sequencing, a reemergence of linkage analyses of all types is
imminent, given both the ability to comprehensively interrogate
very large intervals and to leverage families for gene discovery
that would have been too small to be useful using standard
approaches.
With regard to common variants, despite considerable chal-
lenges and a host of nonreplicated associations, several studies
conducted just prior to the GWAS era resulted in notable find-
ings. These included the identification of EN2 (Benayed et al.,
2005, 2009), theMET oncogene (Campbell et al., 2006; Jackson
et al., 2009), and CNTNAP2 (Alarco´n et al., 2008; Arking et al.,
2008; Vernes et al., 2008). All three have shown some evidence
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due in part to their absence from the most promising results
emerging from recent genome-wide association studies, though
as noted below, there is considerable uncertainty regarding the
current validity of this metric.
As with other areas of medicine, GWAS have emerged as the
gold standard for the identification of common alleles carrying
small effects and three relatively large studies in autism have
recently been completed. The first included 780 families and
an additional 1204 probands and identified significant associa-
tion of ASD to an intergenic region of chromosome 5p14.1
mapping between the neuronal adhesion molecules Cadherin 9
and Cadherin 10 (Wang et al., 2009). The second involved
a cohort of 1031 families and found association to a SNP near
the gene Semaphorin 5A (Weiss et al., 2009) and a third used
a discovery cohort of 1558 individual and found genome-wide
evidence for association at the MACROD2 locus (Anney et al.,
2010). As a likely reflection of both the heterogeneity of ASD
and the challenge of identifying alleles of very modest effect,
none of these studies confirmed the others’ findings.
While the field certainly hoped for replication of identical SNPs
across these samples, the data are nonetheless consistent with
similar studies of complex conditions. Despite cohort sizes that
would be considered large for child psychiatry, none of these
studies were well powered to replicate findings from the others
(Anney et al., 2010). In addition, a comparison of these results
with the candidate gene studies mentioned above underscores
additional questions regarding both the impact of phenotypic
heterogeneity and the best approach to addressing this
problem. Both the MET and CNTNAP2 literature provide
evidence that association is robust either within a specific
subgroup of affected individuals or with an endophenotype as
opposed to a categorical diagnosis.
There has been a long-standing interest across all of psychi-
atry in leveraging endophenotypes, phenomena that fall along
the path from genetic variation to the syndromal clinical presen-
tation. This is understandable given the clear limitations inherent
in categorical diagnostic approaches. The identification of more
homogenous, biologically relevant, and heritable entities would
seem virtually guaranteed to empower genetic studies and aid
in the identification of risk alleles. The challenges in ASD, and
for other neuropsychiatric phenotypes, include the difficulty in
identifying relevant phenomenon a priori and the related
confound of multiple comparisons if a variety of possibilities
are examined through the course of a study. Moreover, it is worth
noting in the instances where loci contributing to ASD have been
most convincingly demonstrated that similar or identical rare
mutations appear to confer a very broad range of phenotypes.
These results suggest that the effective ‘‘distance’’ between vari-
ations in the sequence or structure of the DNA and resulting brain
phenotypes may be quite large. Indeed, it is difficult to imagine in
retrospect what endophenotype would have been useful to
detect these mutations, though admittedly the situation may
be different for common versus rare variants. Finally, it is worth
noting that in other areas of medicine, common variant discovery
has been highly successful even for heterogeneous disorders
using a combination of clinical diagnoses and large cohorts.
Given the magnitude of effects identified in those studies andthose so far suggested by the initial GWAS in ASD, it is clear
that the field is just now approaching the sample sizes necessary
to begin to answer the question of common variant contribu-
tions. One thing is certain: as definitive replicated common vari-
ants are identified, the ability to then clarify relevant endopheno-
types and a range of genotype-phenotype correlations will be
dramatically enhanced.
Molecular Findings and Diagnostic Boundaries
As suggested above, one of the most interesting and thought
provoking recent observation in the field has been the wide
range of neuropsychiatric manifestations that now appear to
emerge from identical rare variants. Indeed the conceptual chal-
lenge of integrating the co-occurrence of ID and ASD pales in
comparison to that posed by the possibility that functionally
identical mutations may lead to ASD, ID, seizure disorder,
schizophrenia, ADHD, Tourette syndrome, OCD, or some
combination of the above. Nonetheless data both from structural
and sequencing studies suggests this may be the case: For
example, 22q11.2 deletions, have long been implicated in the
risk for psychosis in addition to the evidence with regard to
ASD (Guilmatre et al., 2009; Vassos et al., 2010); CNVs at
16p11.2 have been observed in individuals with schizophrenia
(Weiss et al., 2008), a finding that has been solidly supported
by a large case control association analysis (McCarthy et al.,
2009) and de novo mutations in SHANK3 have been identified
in individuals with schizophrenia as well as those with ASD
(Gauthier et al., 2010). Structural variations at CNTNAP2 have
been reported not only in ASD and schizophrenia but Tourette
syndrome as well (Friedman et al., 2008; Verkerk et al., 2003),
and this overlap has also been observed with regard to NLGN4X
(Lawson-Yuen et al., 2008).
At present the data pointing to overlapping risks for schizo-
phrenia and ASD at the 16p11.2 locus is particularly compelling
(McCarthy et al., 2009), with the prevailing hypothesis that dupli-
cations predispose to schizophrenia and a variety of other devel-
opmental outcomes including ASD, while deletions do not seem
to play a prominent role in the risk for psychosis. The prospect of
any shared molecular mechanisms is somewhat ironic. Autism
was initially conceptualized as a form of childhood psychosis,
but with advances in standardized diagnostic approaches, this
idea was rejected (Volkmar and Pauls, 2003). While there is
some overlap between ASD and the social withdrawal seen in
individuals with schizophrenia, the natural history of the latter
is quite distinctive versus the early onset that defines ASD, as
are the positive symptoms of schizophrenia: auditory hallucina-
tions and delusions have not been described as more common
among individuals with idiopathic ASD.
Not surprisingly, the suggestion of convergence among so
many developmental neuropsychiatric disorders opens the
door to a variety of interesting debates. As suggested above,
the notion of diagnostic substitution has been raised, but this
would seems unlikely to explain all of the recent data given the
range of signs and symptoms involved and the strikingly distinct
developmental profiles. Of course, given the demonstration of
incomplete penetrance for most of the implicated variants, it is
also likely that some of the observations are incidental findings.
This possibility underscores the importance of the type of
large-scale association analysis reported by McCarthy et al.Neuron 68, October 21, 2010 ª2010 Elsevier Inc. 261
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provide clear answers to these questions. Finally, as noted, the
apparently broad range of phenotypic outcomes emerging
from what appear to be identical mutations also poses some
interesting challenges to the model that suggests the overlap
of ID and ASD is a reflection of genes for the former uncovering
the normal distribution of ASD traits in the population (Figure 2A).
These observations would seemmore consistent with amodel of
highly pleiotrophic effects of mutations influencing fundamental
neurobiological processes (Figure 2B).
Emerging Neurobiological Models
At the molecular level, evidence in favor of this notion has begun
to converge at the synapse. The identification of NLGN4Xmuta-
tions and the independent findings of rare variants in NRXN1,
SHANK3, and SHANK2 have further focused attention on the
function of neuroligin-neurexin complex and related molecules
in the post synaptic density (PSD), a specialized region of the
excitatory synapse (Figure 3).
Perhaps most interestingly, this data converges with the
evidence pointing to a key role for the fragile Xmental retardation
protein at glutamatergic synapses (Bear et al., 2004; Huber et al.,
2002; Nakamoto et al., 2007). The elaboration of this biology has
led to an intriguing hypothesis: that the cognitive and social
phenotypes may be mediated through deficits in plasticity
relating to long-term depression and that this process is poten-
tially reversible via targeting of metabotropic glutamate recep-
tors or related signaling cascades (Bear et al., 2004; Do¨len
et al., 2010). The notion, supported by recent model systems
data (Chang et al., 2008; Do¨len et al., 2007), that fragile X
syndrome may reflect a dynamic ongoing process and be
amenable to intervention throughout the life span is now being
translated into clinical trials in individuals with fragile X as well
as with idiopathic ASD.
The intersection of studies of syndromic and idiopathic autism
has also focused attention on the PI3K-AKT-mTOR pathway. As
noted, there is strong evidence that rare mutations in TSC-1/
TSC-2 increase the risk for ASD; the data in this regard for
NF-1 andPTEN are also convincing (Butler et al., 2005; Buxbaum
et al., 2007). These molecules point to the rapamycin-sensitive
mTOR-raptor complex, a key regulator of protein synthesis
and cell growth. Further, binding of hepatocyte growth factor
to theMET oncogene results in activation of a variety of signaling
cascades, a process that is regulated in part by PTEN. These
findings point to two intriguing possibilities: first, that targeting
of this pathway, as is feasible with rapamycin and other
compounds, may provide a novel avenue for treatment (Ehninger
et al., 2009; Ehninger et al., 2008), and second, that the data may
converge with the biology implicated by fragile X to further refine
the understanding of the molecular mechanisms leading to
human developmental disorders (Narayanan et al., 2007;
Sharma et al., 2010).
Of course, the question of whether the pathways implicated by
syndromic ASD, which anchor both the mGluR and mTOR
hypotheses, may have broader relevance for idiopathic ASD
remains open. Ongoing studies, both to further elaborate basic
neurobiology and to address the issue in the clinic, will help
provide the answers. What is indisputable is that the conceptual
transition reflected in these efforts is remarkable: the notion that262 Neuron 68, October 21, 2010 ª2010 Elsevier Inc.intellectual disability and ASD associated with FMRP or TSC-1
mutations may not set in stone early in development represents
a seismic shift in thinking regarding the opportunities to
treat these conditions and underscores the transformative
potential of the interplay of human genetic findings and basic
neurobiology.
A third area of possible traction in the neurobiology of ASD
relates to CNTNAP2. As noted, the initial genetic evidence impli-
cating homozygous truncating mutations in ID, seizures, and
ASD was quite strong. Moreover, the investigators who mapped
the locus in Old-Order Amish had the unusual opportunity to
examine pathological specimens, due to surgical intervention
for the severe epilepsy phenotype. The gross morphological
abnormalities included temporal lobe dysplasia, evidence of
abnormal cortical migration, and dysmorphic pyramidal
neurons. Given many remaining uncertainties regarding the
function of CNTNAP2 in the CNS and some evidence for the
presence of the protein at the synapse (Bakkaloglu et al.,
2008), overlap with the previously described pathways has not
been ruled out. Equally interesting, however, is the suggestion,
based on the expression of CNTNAP2 in postmitotic neurons
in the developing human cortex and the aforementioned patho-
logical data, that subtle abnormalities in cortical migration or
organization might be an independent avenue to ASD.
When viewed in a more global sense, the recent large-scale
studies of ASD have begun to suggest other interesting possibil-
ities; the use of pathway analysis to integrate the very large
amount of rare variation emerging from CNV studies has pointed
to the ubiquitin pathway, neuronal adhesion molecules and
those involved in cellular proliferation, projection, and motility,
and GTPase/Ras signaling. A review of the data on 16p11.2
and other specific recurrent CNVs is also focusing attention on
dosage sensitivity in conferring risk and shaping developmental
outcomes (Toro et al., 2010). The further pursuit of these types of
leads will be helped tremendously by additional definitive
genetic findings that allow for prioritization among the various
possibilities, lend greater specificity to testable hypotheses,
and provide a clear link to the human phenotype.
Tourette Syndrome
The history of the genetics of Tourette syndrome (TS) has been
similar in many respects to that described for autism and related
conditions. However, in contrast to the tremendous attention
focused on gene discovery in ASD and the voluminous literature,
particularly over the last 5 years, the scale of the TS genetics
effort has been relatively modest. The types of resources that
have facilitated a high level of productivity in other areas of
psychiatry and clinical neuroscience, including large patient
cohorts and widely accessible biomaterials are just now begin-
ning to be consolidated. Nonetheless, several recent genetic
findings have provided promising leads regarding molecular
mechanisms, cytogenetic and CNV data point to the important
contribution of rare variants, and the first large-scale GWAS
study will soon be completed.
TS is defined by the persistence of unwanted, brief, repetitive,
nonrhythmic motor movements and vocalizations. It is a proto-
typical developmental disorder with an age of onset of between
3 and 8 years (mean 7 years) and a tendency toward
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(Bloch et al., 2006). While the diagnosis requires only the pres-
ence of both vocal andmotor tics, the vast majority of individuals
who present clinically suffer from other psychiatric syndromes:
up to 50% of TS probands suffer from obsessive compulsive
disorder (do Rosa´rio and Filho, 1997; Ghanizadeh andMosallaei,
2009); 50%–90% have co-occurring attention deficit hyperac-
tivity disorder (Burd et al., 2005; Freeman, 2007; Ghanizadeh
and Mosallaei, 2009; Leckman, 2003; Roessner et al., 2007;
Stewart et al., 2006), and there is an apparently increased risk
for both depression and anxiety apart from OCD (Coffey et al.,
2000; Kurlan et al., 2002). These high rates of comorbidity are
likely a consequence of a combination of selection bias (as
epidemiological studies suggest that only a small percentage
of individuals with tics or TS present to clinic); the possibility of
a shared genetic liability as has been best documented for
OCD (Pauls, 2001), and the possibility of a shared neurobiolog-
ical substrate among these conditions. Typically, individuals
with a TS spectrum disorder, meaning TS, chronic tics (either
motor or vocal), or tics with OCD are considered to be affected
for the sake of genetic studies. In addition, within TS pedigrees,
family members with OCD alone are often included as affected
individuals.
Genetic Findings
Twin data, though cumulatively representing a small number of
studies and subjects, suggests a significant genetic contribution
to TS. Monozygotic twin concordance rates are estimated at
50%–77% compared to 10%–23% for dizygotic twins (Price
et al., 1985), with the range dependent on whether TS spectrum
conditions are included. However, despite a longstanding
consensus that genetics plays a key role in disease etiology,
there are, as of yet, no confirmed, replicated genetic risk factors
for TS and related conditions.
Early studies focusedon largemultigenerational pedigrees that
seemed to point to single gene autosomal-dominant inheritance
(Baronet al., 1981;Curtis et al., 1992;KiddandPauls, 1982;Pauls
and Leckman, 1986). However, over time, as the techniques for
mapping Mendelian disorders reached maturity, no TS locus
was identified and a high rate of bilineal inheritance was noted
(McMahon et al., 1996); this hypothesis was abandoned. Subse-
quent segregation analyses (Hasstedt et al., 1995; Kurlan et al.,
1994; Walkup et al., 1996) led to the current characterization of
TS as a complex, heterogeneous genetic disorder.
By the late 1990s, the lack of results from parametric analyses
resulted in a shift toward nonparametric linkage. In 1999, The
Tourette Syndrome Association International Consortium for
Genetics reported a study of 92 affected sib pairs which resulted
inmultipoint maximum-likelihood scores of > 2 on chromosomes
4q and chromosome 8 (Tourette Syndrome Association Interna-
tional Consortium for Genetics, 1999). However, when the study
was extended to 238 sib pairs and 18 large families, evidence for
linkage in these regions diminished, and suggestive evidence
emerged on chromosome 2p (Tourette Syndrome Association
International Consortium for Genetics, 2007). Several other
linkage studies have resulted in LOD scores either approaching
or reaching statistical significance (Breedveld et al., 2010; Curtis
et al., 2004; Me´rette et al., 2000; Paschou et al., 2004); however,
as of yet, only one, described in more detail below, has led to theidentification of mutations altering the structure or function of
transcripts mapping within or near these intervals.
Common variant candidate association studies have been
widely employed and a variety of biologically plausible candidate
genes have been assessed, including various dopamine recep-
tors, the dopamine transporter, noradrenergic transcripts, tyro-
sine hydroxylase, SLC6A3, and a several serotonergic genes
(Barr et al., 1996; Brett et al., 1995; Chou et al., 2004). These
efforts involved samples sizes that would now be considered
inadequately powered to detect common variant risks of plau-
sible magnitude. Not surprisingly, they have not yet resulted in
consistent and reproducible findings.
While the search for common alleles has predominated, there
has also been a steady effort to evaluate the contribution of rare
alleles, almost entirely reflected in outlier studies. Many of these
were reported prior to the CNV era and involved mapping of de
novo chromosomal abnormalities: For example, Petek et al.
(2001) reported a de novo duplication disrupting IMMP2L (inner
mitochondrial membrane protein 2L) and four independent
studies described rearrangements at the chromosome 18q22
region with breakpoints mapping approximately within 1 Mb of
each other. However no missense or nonsense mutations been
identified in IMMP2L or in 18q22 transcripts, though the number
of screened individuals has been very small.
Two similar findings are notable for their overlap with the ASD
literature: An insertion of chromosome 2p21–p23 at 7q35–q36
was found to disrupt CNTNAP2 in three affected individuals
from one family (Verkerk et al., 2003), and Lawson-Yuen et al.
(2008) reported a pedigree with a transmitted NLGN4X deletion
involving exons 4, 5, and 6. The proband had autism as well as
motor tics, while his sibling who also carried the deletion was
diagnosed with TS and ADHD. The carrier mother was reported
to have a learning disorder, anxiety, and depression. Again,
large-scale sequencing of TS probands has not been reported
for either transcript.
In a study from our laboratory that has become the subject of
some contention, Abelson and colleagues (2005) reported a de
novo chromosome 13 inversion in a sporadic TS pedigree
mapping 350 kb from the transcript Slit and Trk-like, Family
Member 1 (SLITRK1). Subsequent sequence analysis of 174
unrelated probands revealed a single nucleotide deletion pre-
dicted to result in a prematurely truncated protein that segre-
gated with TS and trichotillomania (compulsive hair pulling)
(TTM) in the small family in which it was identified. Two indepen-
dent occurrences of a rare single base change (var321) in a highly
conserved region of the SLITRK1 30UTR, corresponding to the
binding site for the microRNA hsa-miR-189, were also identified.
In vitro methods were used to demonstrate the functional conse-
quences both of the coding and 30UTR variations and haplotype
analysis was performed to test whether the UTR variants were
independent. Screening of more than four thousand controls re-
sulted in a nominally significant association with TS (p = 0.0056).
Subsequent genetic studies of SLITRK1 have yielded incon-
sistent results. Resequencing of individuals with TS has not
revealed additional obviously pathogenic coding mutations
(Chou et al., 2007; Deng et al., 2006; Zimprich et al., 2008). A
common variant candidate gene study in a small cohort found
significant association (Miranda et al., 2009) and several rareNeuron 68, October 21, 2010 ª2010 Elsevier Inc. 263
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tified in (Zuchner et al., 2006); however, the small sample size of
the former and the absence of a bona fide mutation burden anal-
ysis is the latter limited the conclusions that could be drawn from
either study.
Two publications have specifically evaluated the rare variant
var321 (Keen-Kim et al., 2006; Scharf et al., 2008). Given the
extreme low-allele frequency, neither had the sample size
necessary to conduct meaningful statistical analyses. However,
both noted that the variant, while present in affected family
members, appeared to be neither necessary nor sufficient for
TS in some of these pedigrees and both found a high proportion
of affected families of Ashkenazi descent that carried var321,
leading to the contention that our initial report was an incidental
finding confounded by population stratification.
As discussed above, the criteria implicitly employed in these
studies would be appropriately applied to alleles purported to
carry Mendelian risks but provides little evidence for or against
association of var321. Moreover, our laboratory subsequently
tested the hypothesis that population stratification due to occult
Ashkenazi ancestry led to the initial finding (O’Roak et al., 2010).
Using a combination of genome-wide genotyping data, amultidi-
mensional scaling analysis and dense haplotype mapping we
found no evidence to support the conclusion that occult ethnicity
confounded our results. Instead the additional data provided
further evidence that the two instances of var321 seen in the
initial probands were on distinct haplotypes, suggesting either
recurrent independent mutations or the sharing of an ancient
allele by affected individuals, with either alternative providing
additional support for the association with TS.
To date, only a single genome-wide study has been published
of structural variation and this included 111 individuals (Sun-
daram et al., 2010). Despite careful attention to potential
confounds including population stratification and batch effects,
the small sample size limited the ability of the authors to arrive
at definitive conclusions. However, recurrent CNVs were identi-
fied at loci previously implicated in ASD and schizophrenia,
including NRNX1 and the chromosome 1q21 region.
Finally, a recent study from our laboratory used parametric
linkage to identify a rare functional nonsense mutation in the
gene segregating with TS in a dense pedigree (Ercan-Sencicek
et al., 2010). A family with a father and eight offspring meeting
DSM-IV-TR criteria for TS and no evidence for bilineal inheri-
tance was mapped using parametric linkage. Genome-wide
analysis identified a single region reaching the maximum theo-
retical LOD score for the pedigree (Lod = 2.1). Sequencing of
all genes within the interval led to the discovery of a single rare
coding mutation, a premature termination codon (W317X) in
the gene L-histidine decarboxylase (HDC), the rate-limiting
enzyme in histamine biosynthesis. Given experimental evidence
for incomplete or absent nonsense-mediated decay, and the
knowledge that the wild-type (wt) HDC protein forms an active
homodimer, themutant protein was evaluated for possible domi-
nant negative effects, and this was confirmed in in vitro studies.
Genetic Findings and Emerging Models
Given the paucity of specific genetic findings, the ability of gene
discovery efforts to define molecular models remains limited,
and a comprehensive consideration of the data regarding neuro-264 Neuron 68, October 21, 2010 ª2010 Elsevier Inc.anatomical studies of TS is beyond the scope of this review.
Briefly, attention has been focused on the cortical striatal-tha-
lamo-cortical circuitry that mediates the integration of move-
ment, sensation, emotion, and intention. This long-standing
interest is supported by analogy to other movement disorders,
model systems studies, and neuroimaging data, and recent
neuropathological findings pointing to abnormalities in straital
cholingeric and GABAergic interneurons (Kalanithi et al., 2005;
Kataoka et al., 2010).
There has also been a longstanding focus in the TS field on
dopaminergic (DA) neurotransmission. In addition to analogies
to other movement disorders, this interest is driven in part by
the clinical observation that DA blockade is the most effective
and reliable pharmacological means in the current armamen-
tarium to transiently reduce tics (Scahill et al., 2006). Moreover
DA agonists may engender tics and other stereotypes in individ-
uals both with and without TS. However, neither genetic or neu-
roimaging studies have so far been definitive and overall the
nature of the molecular mechanisms underlying TS remain
elusive (Harris and Singer, 2006; Singer, 2005).
As noted, strong genetic findings in TS are limited and conse-
quently the relevance of the biology of isolated outlier cases
remains uncertain: SLITRK1 has been pursued on several fronts.
Our laboratory in collaboration with Angeliki Louvi reported on
the conserved and developmentally regulated pattern of expres-
sion of SLITRK1 in CTSC circuits, highlighting both mRNA and
protein expression in cholinergic interneurons and the striosomal
compartment (Stillman et al., 2009); Kajiwara and colleagues
(2009) found evidence that the previously noted regulation of
neurite outgrowth (Aruga and Mikoshiba, 2003) is mediated by
binding to 14-3-3 molecules; and Katayama et al. (2010)
described an anxiety phenotype and evidence for increased
noradrenergic neurotransmission in the mouse knockout. A
particularly intriguing recent result has been the finding of exces-
sive grooming, a putative obsessive-compulsive phenotype, in
the mouse knockout of the closely related molecule, SLITRK5
(Shmelkov et al., 2010).
The identification of a highly penetrant mutation in the gene
L-histitide Decarboxylase (HDC) in a dense pedigree with TS
provides a separate but potentially direct link to prior hypotheses
regarding the involvement of DA pathways in TS: histaminergic
(HA) neurotransmission is mediated by four known G protein-
coupled receptors; HA in the CNS is known to modulate arousal,
cognition, movement, and behavior, and while the biological
implications are not yet clear, both histamine 2 (H2R) and hista-
mine 3 (H3R) receptors are enriched in the human and rodent
striatum (Haas et al., 2008). H3R is of particular interest as it
acts as a presynaptic autoreceptor on HA containing projection
neurons, with activation leading to decreased synthesis and
release. It also functions as a presynaptic receptor on non-HA-
containing neurons, regulating a variety of neurotransmitters,
including DA and serotonin; and as a postsynaptic receptor
that has been shown to colocalize with and modulate signaling
through both D1 and D2 receptors in the striatum.
While HDC null mice are viable and exhibit no structural
brain abnormalities, they have shown decreased brain HA and
increased sensitivity to stereotypic behaviors upon administra-
tion of DA agonists (Kubota et al., 2002). Such stimulant-induced
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ously been proposed as a model of human tics (Saka and Gray-
biel, 2003). Taken together, these data point to the possibility
that decreased HA synthesis and/or release in the CNS, whether
mediatedbyHDCmutation or other processes, could predispose
to or augment tics. Consistent with this hypothesis, studies of
selective H3R antagonists and inverse agonists which increase
histaminergic neurotransmission have been shown to moderate
the effects of stimulants in rodent models (Fox et al., 2005),
although a very recent study has called the extent of the effect
into questioned (Burban et al., 2010).
Finally, H3R compounds have already entered early clinical
trials, have a reportedly favorable side effect profile, and are
being evaluated for a variety of neuropsychiatric indications.
The convergence of the human genetic and model systems
data and the potential availability of clinically useful compounds
being investigated in related psychiatric conditions suggests
a surprisingly direct avenue to test empirically the generalizabilty
of the biology implicated by gene discovery in a single highly
unusual pedigree.
Summary, Conclusions, and Future Prospects
The foregoing has highlighted both the tremendous promise as
well as the considerable challenges that continue to face the
study of the genetics of child psychiatric disorders, and ASD
and TS in particular.
With regard to ASD, this review points to several overarching
conclusions: (1) that despite notable progress, many current
findings are not yet as definitive as in other areas of medicine;
(2) that some of this uncertainty reflects the tremendous locus
heterogeneity of this syndrome as well as the inherent difficulty
in establishing association of rare alleles—either those that are
de novo or conferring moderate risks; (3) that it would be entirely
premature to minimize the importance of common variant
studies, as ASD samples are just now reaching a point where
well-powered analyses can realistically investigate the contribu-
tion of common alleles carrying plausible risks; and (4) that even
a relatively small number of unambiguous genetic findings,
whether with regard to common or rare variants, hold the poten-
tial to elaborate relevant molecular mechanisms.
With regard to TS, the conclusions are quite similar, but, as
noted, the field has been comparatively slow to leverage
emerging technologies due to limited patient resources. None-
theless, the findings to date point to overlapping risks with other
neurodevelopmental disorders, a theme that is extending across
all of psychiatry. Moreover, the recent HDC findings from our
group highlight a more general theme regarding the opportuni-
ties that may be afforded by simultaneous rapid progress across
scientific disciplines. Given parallel advances in neurobiology
and pharmacology, the speed with which genetic findings may
be found to translate into clinically relevant investigations also
promises to accelerate.
Finally, the review has focused on the promise that gene
discovery has to drive neurobiological studies yielding novel
insights into the molecular mechanisms of child psychopa-
thology. As noted throughout, this has so far been most notable
with regard to syndromic presentations and outliers, the chal-
lenges of arriving at a necessary level of certainty regardinggenetic findings in idiopathic ASD and TS remains considerable.
At the same time, the tools necessary to do so are clearly
present. The consolidation of very large samples, the ability to
feasibly query every base of the human exome and the imminent
ability to do so cross the entire human genome, thematuration of
proven methods to confirm association in multigenic complex
disorders, and the manner in which new technologies are em-
powering both pedigree-based and case-control studies, all
suggest that the optimism that characterizes the field is well
founded.
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